Cystic Fibrosis Related Diabetes
- 1.6k Downloads
Improved life expectancy in cystic fibrosis (CF) has led to an expanding population of adults with CF, now representing almost 50 % of the total CF population. This creates new challenges from long-term complications such as diabetes mellitus (DM), a condition that is present in 40 %–50 % of adults with CF. Cystic fibrosis-related diabetes (CFRD) results from a primary defect of insulin deficiency and although sharing features with type 1 (DM1) and type 2 diabetes (DM2), it is a clinically distinct condition. Progression to diabetes is associated with poorer CF clinical outcomes and increased mortality. CFRD is not associated with an increased risk of cardiovascular disease and the prevalence of microvascular complications is lower than DM1 or DM2. Rather, the primary goal of insulin therapy is the preservation of lung function and optimization of nutritional status. There is increasing evidence that appropriate screening and early intervention with insulin can reverse weight loss and improve pulmonary function. This approach may include targeting postprandial hyperglycemia not detected by standard diagnostic tests such as the oral glucose tolerance test. Further clinical research is required to guide when and how much to intervene in patients who are already dealing with the burden of one chronic illness.
KeywordsCystic fibrosis Diabetes CF-related diabetes Hyperglycemia Insulin Lung function
Compliance with Ethics Guidelines
Conflict of Interest
Donal O’Shea and Jean O’Connell declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 3.••Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32:1626–31. This paper reported data from a US CF center where early diagnosis and aggressive treatment of CFRD was associated with a significant narrowing of the gap in mortality between those CF patients with and without diabetes.PubMedCentralPubMedCrossRefGoogle Scholar
- 12.Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol. 2001;32:343–50.PubMedCrossRefGoogle Scholar
- 17.••Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care. 2010;33:2677–83. A comprehensive review published at the same time as the CFRD consensus conference clinical care guidelines. PubMedCentralPubMedCrossRefGoogle Scholar
- 43.••Waugh N, Royle P, Craigie I, Ho V, Pandit L, Ewings P, et al. Screening for cystic fibrosis-related diabetes: a systematic review. Health Technol Assess. 2012;16:iii–iv:1–179. A comprehensive and informative review of currently recommended and potentially more appropriate screening methods for CFRD.Google Scholar
- 46.••Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care. 2009;32:1783–8. This study confirmed that insulin therapy improved CF-specific outcomes in CFRD without fasting hyperglycemia.PubMedCentralPubMedCrossRefGoogle Scholar
- 48.••Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33:2697–708. The most up-to-date recommendations for clinical practice in CFRD.PubMedCentralPubMedCrossRefGoogle Scholar
- 55.Management of Cystic Fibrosis Related Diabetes Mellitus: Report of the UK Cystic Fibrosis Working Group. UK CF Trust; 2004.Google Scholar
- 63.Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–67.CrossRefGoogle Scholar
- 75.Stack M, Mahony M, Boyle C. Obesity in childhood cystic fibrosis (Abstract 220). J Cyst Fibros. 2007;6(Suppl):S54.Google Scholar
- 86.Tierney S, Webb K, Jones A, Dodd M, McKenna D, Rowe R, et al. Living with cystic fibrosis-related diabetes or type 1 diabetes mellitus: a comparative study exploring health-related quality of life and patients’ reported experiences of hypoglycaemia. Chronic Illn. 2008;4:278–88.PubMedCrossRefGoogle Scholar
- 96.Leclercq A, Gauthier B, Rosner V, Weiss L, Moreau F, Constantinescu AA, et al. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J Cyst Fibros. 2013;S1569–993. [Epub ahead of print].Google Scholar
- 99.Kolouskova S, Zemkova D, Bartosova J, Skalicka V, Sumnik Z, Vavrova V, et al. Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3-year prospective study. J Pediatr Endocrinol Metab. 2011;24(7–8):449–54.PubMedGoogle Scholar